Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Current Medical Research and Opinion 24 (11): 3029-3035; 2008.
Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Chondroitins 4 and 6 Sulfate in Osteoarthritis of Knee. A Randomized, Controlled Trial. Arthritis&Rheumatism. 58(3): 779-786; 2005.
Volpi N. The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment. Current Drug Targets-Immune, Endocrine&Metabolic disorders. 4:119-127;2004.
Uebelhart D, Malaise M, Marcolongo R, DeVathairell F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sul fate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis&Cartilage.12:269-276;2004.
Richy F, Bruyere O, Ethgen O, Cucherat M, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. Arch Intern Med. 163:1514-1522; 2003.
Jordan K.M, Arden N.K, Doherty M, Bannwarth B, Bijlsma J. W. J, Dieppe P et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT) . Ann Rheum Dis. 62: 1145-1155; 2003.
Volpi N. Oral absorption and bioavailability of ichtyic origin chondroitin sulfate in healthy male volunteers.Osteoarthritis&Cartilage.11: 433-441; 2003.
Mathieu P. Un nouveau mode d’action des chondroitines sulfates ACS4-ACS6 dans le cartilage arthrosique. Presse Med. 31 : 1383-1385 ; 2002.
Verbruggen G, Goemaere S, Veys M. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 21: 231-243; 2002.
Volpi N. Oral bioavailability of chondroitin sulfate ( condrosulf ) and its constituents in healthy male volunteers.Osteoarthritis&Cartilage.10: 768-777: 2002.
Du Souich, P., Vergés, J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin. Pharmacol. Ther. 70: 5 - 9; 2001.
Nerucci, F., Fioravanti, A., Cicero, M. R., Collodel, G., Marcolongo, R. Effects of chondroitin sulfate and interleukin-1ß on human chondrocyte cultures exposed to pressurization: a biochemical and morphological study. Osteoarthritis and Cartilage 8: 279 - 287; 2000.
Leeb, B. F., Schweitzer, H., Montag, K., Smolen, J. S. A Metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J. Rheumatol. 27: 205 - 211; 2000.
McAlindon T. E, LaValley M. P, Gulin J. P, Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis. A systematic quality assessment and meta-analysis. JAMA. 283 (11) : 1469-1477; 2000.
Adebowale A.O, Cox D.S, Liang Z, Eddington N.D et al. Analysis of glucosamine and chondroitin sulfate content in marketed products and the caco-2 permeability of chondroitin sulfate raw materials. JANA. 3 (1) : 37-44; 2000.
Ronca, F., Palmieri, L., Panicucci, P., Ronca, G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis and Cartilage 6 (Suppl. A): 14 - 21; 1998.
Pavelka, K., Manopulo, R., Bucsi, L. Double-blind, dose-effect study of oral Chondroitin 4&6 Sulfate 1200 mg, 800 mg, 200 mg and placebo in the treatment of knee osteoarthritis. Litera Rheumatologica 24: 21 - 30; 1998.
Malaise, M., Marcolongo, R., Uebelhart, D., Vignon, E. Efficacy and tolerability of 800 mg oral Chondroitin 4&6 Sulfate in the treatment of knee osteoarthritis: a randomised, double-blind, multicenter study versus placebo. Litera Rheumatologica 24: 31 - 42; 1998.
Verbruggen, G., Veys, E. M. Influence of Chondroitin 4&6 Sulfate on finger osteoarthritis in a double-blind, controlled study versus placebo. Litera Rheumatologica 24: 43 - 47; 1998.
Bourgeois, P., Chales, G., Dehais, J., Delcambre, B., Kuntz, J-L., Rozenberg, S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis and Cartilage 6 (Suppl. A): 25 - 30; 1998.
Bucsi, L., Poor, G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis and Cartilage 6 (Suppl. A): 31 - 36; 1998.
Verbruggen, G., Goemaere, S., Veys, E. M. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis and Cartilage 6 (Suppl. A): 37 - 38; 1998.
Uebelhart, D., Thonar, E. J-M. A., Delmas, P. D., Chantraine, A., Vignon, E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis and Cartilage 6 (Suppl. A): 39 - 46; 1998.
Morreale, P., Manopulo, R., Galati, M., Boccanera, L., Saponati, G., Bocchi, L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J. Rheumatol. 23: 1385 - 1391; 1996.
Conte, A., Volpi, N., Palmieri, L., Bahous, I., Ronca, G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Drug. Res. 45 (2): 918 - 925; 1995.
Conrozier, T., Vignon, E. Die Wirkung von Chondroitinsulfat bei der Behandlung der Hüftgelenksarthrose. Eine Doppelblindstudie gegen Placebo. Litera Rheumatologica 14: 69 - 75; 1992.
L'Hirondel, J. Klinische Doppelblindstudie mit oral verabreichtem Chondroitinsulfat gegen Placebo bei der tibiofemoralen Gonarthrose (125 Patienten). Litera Rheumatologica 14: 77 - 84; 1992.
Conte, A., de Bernardi al., Metabolic fate of exogenous chondroitin sulfate in man, Arzneim.-Forsch./Drug Res., 7(2): 768 - 772; 1991.
Palmieri, L., Conte, A., Giovannini, L., Lualdi, P., Ronca, G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Drug. Res. 40 (1): 319 - 323; 1990.